CRL
Charles River Laboratories International, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -0.9% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 140 | -1 | 45.53M | $10.31B | +6 | −6 |
| Q1 2026 | 143 | -7 | 45.52M | $7.86B | +6 | −14 |
| Q4 2025 | 150 | +3 | 43.69M | $8.72B | +4 | — |
| Q3 2025 | 22 | 0 | 23.18M | $3.62B | +1 | −2 |
| Q2 2025 | 20 | +2 | 21.36M | $3.24B | +4 | −2 |
| Q1 2025 | 15 | 0 | 9.57M | $1.44B | +1 | −1 |
| Q4 2024 | 15 | +1 | 9.65M | $1.78B | +1 | — |
| Q3 2024 | 13 | -1 | 6.67M | $1.31B | — | −1 |
| Q2 2024 | 14 | — | 3.92M | $810.09M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 3 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 9 | State Street Global Advisors ✦ (passive) | 1.90M | -12.8% | $286.38M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 1.26M | +2.5% | $189.94M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 1.26M | +2.5% | $189.94M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Norges Bank ✦ (passive) | 437.81K | -18.3% | $65.90M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 353.58K | New | $53.22M | 0.0% | New | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 282.02K | +65.3% | $42.45M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 282.02K | +65.3% | $42.45M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | PRIMECAP Management ✦ | 272.89K | 0.0% | $41.08M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 255.22K | +9.9% | $38.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 163.34K | +107.1% | $24.59M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 154.78K | +25.1% | $23.30M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 75.97K | -55.6% | $11.44M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 21 | Millennium Management ✦ | 74.50K | -80.0% | $11.21M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | Marshall Wace ✦ | 37.93K | +75.6% | $5.71M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 23 | Marshall Wace ✦ | 37.93K | +75.6% | $5.71M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 24 | Marshall Wace ✦ | 37.93K | +75.6% | $5.71M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 6.24K | -70.3% | $930,224 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 6.24K | -70.3% | $930,224 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 6.24K | -70.3% | $930,224 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 6.24K | -70.3% | $930,224 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 29 | Baillie Gifford ✦ | 49 | -99.9% | $7,375 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $53.22M | 0.0% |
Exited
| D. E. Shaw & Co. | $15.63M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 555 holders, 56.84M shares, $9.32B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.04K sh · $599,711
Director · 573 sh · $163,443
Officer · 3.71K sh · $1.04M
Officer, Director · 6.50K sh · $1.82M
Director · 28.73K sh · $7.90M
Officer · 404 sh · $104,446
Officer · 1.21K sh · $311,529
Officer · 736 sh · $190,278
Officer · 4.18K sh · $1.08M
Officer · 1.27K sh · $330,055
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology